Table 2.

Detailed results of subgroup analysis.

Treatment	Pla	Sul	Toc	Sec	Ixe	Net	Bim	Ris	Ust	Fil	Tof	Upa	Eta	Inf	Ada	Cer	Gol
RR (95% CI) for ASAS40 response	Reference	1.18 (0.76, 1.82)	0.60 (0.22, 1.67)	1.87 (1.28, 2.73)	2.41 (1.73, 3.34)	2.22 (1.14, 4.32)	3.44 (1.53, 7.76)	1.50 (0.62, 3.63)	0.90 (0.61, 1.33)	2.00 (0.94, 4.23)	1.72 (0.97, 3.03)	2.02 (1.14, 3.59)	2.25 (1.72, 2.94)	3.63 (2.23, 5.91)	2.44 (1.80, 3.31)	3.58 (2.37, 5.39)	2.52 (1.89, 3.38)
SUCRA for ASAS40 response, %	12.7	20.4	4.8	44.6	64.3	58.2	83.3	35.4	9.1	51.2	40.4	51.6	58.6	89.8	66.3	89.5	69.2
RR (95% CI) for incidence of SAEs	Reference	1.05 (0.57, 1.96)	1.00 (0.02, 49.45)	0.56 (0.10, 3.07)	0.20 (0.01, 2.72)	2.78 (0.93, 8.30)	1.00 (0.02, 48.28)	1.97 (0.18, 21.13)	0.14 (0.01, 2.68)	0.95 (0.17, 5.27)	3.00 (0.12, 72.15)	0.33 (0.04, 3.04)	0.67 (0.12, 3.94)	0.33 (0.10, 1.04)	2.18 (1.02, 4.68)	3.99 (0.05, 322.63)	0.55 (0.08, 3.67)
SUCRA for incidence of SAEs, %	49.0	54.1	16.8	64.9	62.8	49.3	81.7	66.9	71.6	27.5	67.4	48.4	39.6	54.4	32.8	23.2	39.5

RR: risk ratio; SMD: standardized mean difference; CIs: confidence intervals; SUCRA: surface under the cumulative ranking area; Pla: placebo; Sul: sulfasalazine; Toc: tocilizumab; Sec: secukinumab; Ixe: ixekizumab; Net: netakimab; Bim: bimekizumab; Ris: risankizumab; Ust: ustekinumab; Fil: filgotinib; Tof: tofacitinib; Upa: upadacitinib; Eta: etanercept; Inf: infliximab; Ada: adalimumab; Cer: certolizumab pegol; Gol: golimumab.